FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)

NCT00448019 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Rituximab
DRUG: Bevacizumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]